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In 2011, the International League against Epilepsy (ILAE) proposed a first international consensus of the classification of focal cortical 
dysplasia (FCD). This FCD classification had been widely used in worldwide. In this review paper, the authors would like to give 
helpful comments for better understanding of the current FCD classification. Especially, the basic concepts of FCD type I, such as 
“radial”, “tangential” and “microcolumn” will be discussed with figures. In addition, the limitations, genetic progress and prospect of 
FCD will be suggested.
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INTRODUCTION
Focal cortical dysplasia (FCD) is a heterogeneous group of 
disorders, which can be the cause of drug-resistant epilepsy or 
intractable epilepsy12). In medical practice, “dysplasia” is used 
as variable meanings, as pre-neoplastic (e.g., epithelial dyspla-
sia of stomach), developmental anomaly (e.g., renal dysplasia) 
or etc. Originally “dysplasia” was a term used to refer an ab-
normality of development, alternation in size, shape and orga-
nization of adult cells14,16). Blümcke et al.5) defined this termi-
nology as “any tissue that is imperfectly developed in 
embryonic or fetal life. However, dysplasia is a diagnostic term 
used here to identify specific malformations of the cortex, the 
so-called FCDs, irrespective of their diverse histologic appear-
ances that are addressed by this classification” in their paper5). 
Therefore, it is obvious that FCDs have a meaning of develop-
mental abnormalities including cortical dyslamination, cyto-
architectural lesions, and underlying abnormalities of white 
matter5,11).
THE SHORT HISTORY OF FCD
In 1971, Taylor et al.13) reported the 10 patients with drug-
resistant epilepsy and described several histological findings, 
cortical disorganization, large bizarre neurons and balloon 
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cells which are characteristic findings of the current classifica-
tion of FCDs. In this paper, they described these features as 
“Focal dysplasias of cerebral cortex”. Previously, Crome had 
described three cases of intractable epilepsy. He described 
“dysmorphic neurons” as “giant nerve cells” in his cases7).
After that, many researchers used different various termi-
nologies in discussing FCDs. Although the etiology is exactly 
unknown, it is accepted that many lesions are related to the 
alteration of cortical development caused by a variety of 
mechanisms12). In 1992, Meencke and Veith9) introduced “mi-
crodysgenesis” as a minor parenchymal malformation in pa-
tients with generalized epilepsy. They described many charac-
teristic histological findings from their cases. These findings 
were largely overlapped with the features in current classifica-
tion system of FCD. In 1996, the terminology of “malforma-
tion of cortical development (MCD)” was introduced to desig-
nate collectively a common group of disorders in children 
with developmental delay and young people with epilepsy2). 
They categorized these disorders as group I, II, and III. FCD 
was categorized as group III.B. In the past, MCDs have been 
defined as “neuronal migration disorder”; however, as not all 
the cortical abnormalities have been proven to be due to mi-
grational derangements, the general term of MCDs was pref-
ered1).
In 2004, Palmini et al.11) suggested FCD classification. After 
panel discussion, they proposed as follows : 1) a specific ter-
minology for the different types of abnormal cells encoun-
tered in the cerebral cortex of patients with FCD; 2) a reap-
praisal of the different histopathologic abnormalities usually 
subsumed under the term “microdysgenesis,” and suggested 
that this terminology be abandoned; and 3) a more detailed 
yet straightforward classification of the various histopatho-
logic features that usually are included under the heteroge-
neous term of “focal cortical dysplasia.”
Therefore, they classified the lesions as mild MCD (mild 
MCD) and FCD. In addition, they classified each entity into 
type I and II respectively (Table 1).
With advances in clinical, histological, radiological and ge-
netic understanding of FCDs, International League Against 
Epilepsy (ILAE) Task Force proposed a three tiered classifica-
tion system in 2011.
THE CURRENT ILAE CLASSIFICATION SYSTEM 
OF FCD
It is better to read the original paper5) “point for point” for 
understanding of the detailed FCD classification system. In 
addition, the authors strongly recommend to read Najm et al.’s 
paper10). This paper dealt not only the original classification 
system, but also updated issue along the new data and pro-
spective suggestions.
In this review paper, the authors would like to give helpful 
comments for better understanding of the current FCD classi-
fication.
Overview
The ILAE classification system of FCD is based on some 
several neurodevelopmental studies, especially on Cepeda et 
al.’s study6) in a large portion. They suggested “dysmature ce-
rebral developmental hypothesis” which is a partial failure in 
Table 1. Classification of cortical dysplasias in epilepsy11)
Focal dysplasia 
type
Subtype Main neuropathological features
Mild MCD Type I Heterotopic/excess neurons in layer I
Type II Heterotopic/excess neurons outside in 
layer I
FCD type I Type Ia Cortical dyslamination only (±MCD 
features)
Type Ib Cortical dyslamination+giant* or 
immature neurons†
FCD type II
(Taylor-type)
Type IIa Cortical dyslamination+dysmorphic 
neurons‡
Type IIb Cortical dyslamination+dysmorphic 
neurons and balloon cells
In Palmini’s classification, ‘giant neurons’ were described focusing on cell 
size. In the other hand, ‘dysmorphic neurons’ were described focusing 
abnormal morphology and aggregated coarse Nissl substance. The 
abnormal neurons in Fig. 5B are similar to the ‘giant neurons’ and cells 
in Fig. 6B are more similar to the ‘dysmorphic neurons’ in Palmini et al.’s 
classification. In the current classification, the definition of dysmorphic 
neuron has two morphological features, both large size and the 
characteristic Nissl substance. According to Palmini et al.’s classification11), 
*giant neurons are neurons of increased size (compared with layer V 
pyramidal neurons) with central nuclei. †The immature neurons are 
round cells with immature nucleus, not dysmorphic or giant. They could 
be seen in heterotopic nodules. ‡Dysmorphic neurons are cells with 
abnormal orientation, size, cytoskeletal structures and atypical dendritic 
processes. Nissl substance can be seen in clumps. MCD : malformation of 
cortical development, FCD : focal cortical dysplasia
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later phases of cortical development might show the distinc-
tive histopathology, such as cortical dysplasia And local inter-
actions of dysmature cells with normal postnatal neurons 
might promote seizures. Especially the basic concept of FCD 
type I was established from the Hildebrandt et al.’s morpho-
metric study8).
On contrary to Palmini et al.’s system11), The ILAE classifi-
cation system of FCD has a three-tier system. This system 
composed of isolated FCDs (FCD type I and II) and variants 
associated with other (potentially) epileptogenic lesions (FCD 
type III). The definition of FCD type III was cortical dyslami-
nation abnormalities associated with a principal lesion, usual-
ly adjacent to or affecting the same cortical area/lobe3). The 
basic concept of type III seems to base on that there were some 
disturbances of normal cortical six layers adjacent the main 
lesion. In addition, it might be very difficult to identify these 
“subtle” cortical abnormalities from the histologic changes of 
“secondary reactive process, resulting from the main lesions.
Meanwhile, the mild MCD (mMCD) was not included the 
current system3). Therefore, the mMCDs in Blümcke et al.’s 
paper4) were classified according to the Palmini et al.’s classifi-
cation11).
To get the best possible histologic assessment and reduce 
sampling errors, the standardized procedures for inspection, 
distribution and processing of epileptogenic brain tissue are 
very important3). Especially, the surgical procedures, resulting 
on piecemeal fragmentations of tissue should be avoided for 
pathologic diagnosis. The Task Force of ILAE commission on 
Diagnostic Methods suggested the International recommen-
dation for a comprehensive neuropathologic workup of epi-
lepsy surgery brain tissue3). They emphasized an en-bloc resec-
tion, anatomical oriented landmarks and 5 mm serial cutting, 
perpendicular to the pia. The immunohistochemical staining 
had become a routine procedure for the diagnosis. For exam-
ple, the neuronal markers (e.g., NeuN) are essential to diagno-
sis certain type of FCD, especially in type I.
They defined the words, “dual pathology” and “double pa-
thology”. They proposed the “dual pathology” as only in hip-
pocampal sclerosis (HS), a second principal lesion affecting 
the brain, that is, tumor, vascular malformation, glial scar, 
limbic/Rasmussen encephalitis, or MCD (including FCD type 
IIa/IIb)5). If there is an architectural abnormality in the tem-
poral lobe in HS patients, we should diagnosis as FCD type 
IIIa, instead of FCD type I or dual pathology. The double pa-
thology meant that two independent lesions affecting one or 
multiple lobe, without HS. It meant that both lesions might 
originate from independent pathogenesis. For example; cav-
ernous angioma in right temporal lobe and ganglioglioma in 
left temporal lobe.
In summary, 1) If HS plus FCD type I features in the temporal 
lobe is FCD type IIIa. 2) If HS plus other lesion (FCD type II, tu-
mor, scar, or encephalitis) is a dual pathology. And 3) lesion A 
Fig. 1. The low power view of normal neocortex (NeuN, ×40) and a 
Korean folding pan (inlet). The imaginary white lines show the direction 
of radial migrations of neural cells. The lines look like the bones of a 
folding pan (inlet). The cortical six-layers were seen with red imaginary 
lines. The red imaginary lines show the tangential composition of 
neocortex. In the normal neocortex, it is unusual that the neuronal cells 
exactly align along the white imaginary lines. 
Fig. 2. The low power view of the neocortex in FCD type Ia (NeuN, ×40). 
In contrast to the normal neocortex, many neuronal cells in FCD type Ia 
show linear alignment as shown in the dot-line box. FCD : focal cortical 
dysplasia.
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(except HS) plus lesion B (except HS) is a double pathology.
The clinico-radiologic-pathological correlation is very es-
sential in diagnosis. For example, the histological features of 
hemimegalencephaly, tuberous sclerosis or schizencephaly 
could be overlapped with FCD type II5). Comprehensive re-
view of patient clinical information would provide a diagnos-
Fig. 3. In high power view of the box (NeuN, ×200), the so-called many 
microcolumns, which were defined more than eight neurons aligned in a 
vertical direction, are noted (red boxes).
Fig. 4. The low power view of FCD type Ib (NeuN, ×40). The cortical six-
layers are deranged (too chaotic) compared to those in normal 
neocortex (Fig. 1). FCD : focal cortical dysplasia.
A B C
Fig. 5. The histopathological findings of FCD type IIa. The low power view (A; H-E, ×40) shows cortical dyslamination which means derangement of normal neo-
cortical six-layers. High power view shows many large dysmorphic neurons with coarse Nissl substances. The size of dysmorphic neuron cytoplasm is more than 
20 µm (B; H-E, ×400; black bar, 20 µm). Dysmorphic neurons are highlighted by immunostaining with nonphosphorylated neurofilament (C; SMI132, ×200). FCD : 
focal cortical dysplasia.
A B C
Fig. 6. The histopathological findings of FCD type IIb. The low power view (A; H-E, ×40) shows cortical dyslamination as FCD type IIa. High power view shows 
many large dysmorphic neurons with coarse Nissl substances (B; H-E, ×400; black bar, 20 µm) and balloon cells showing eosinophilic homogenous cytoplasm (C; 
H-E, ×400; black bar, 20 µm). FCD : focal cortical dysplasia.
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tic clue.
FCD type I
FCD Type I is a malformation characterized by abnormal 
cortical layering, which is caused by abnormal process in ei-
ther radial migration of neurons (FCD type Ia) or the six-lay-
ered tangential composition of the neocortex (FCD type Ib). 
The combination of both conditions will be classified as FCD 
type Ic5). Before the understanding of the pathology of FCD 
type Ia, we have to remind what are “radial” and “tangential” 
(Fig. 1). Because the neuronal progenitor cells migrate along 
the radial glial cells, the radial migration looks like the bones 
of “a folding pan (Fig. 1, inlet)” in the microscopic examina-
tion (Fig. 1, white lines). And it is important to understand the 
definition of “microcolumn”5). The definition of “microcol-
umn” is more than eight neurons aligned in a vertical direc-
tion (Figs. 2 and 3). The concept of microcolumn was firstly 
introduced in Hildebrandt et al.’s paper8). On their observa-
tion, the cells of microcolumn had smaller perikarya. During 
the developmental period, primitive neuronal cells start to 
differentiate to several types and sizes after 22-weeks of gesta-
tion and the microcolumns begin to disappear10). The pattern of 
microcolumn is unusual histological findings in postnatal con-
trols8) (Fig. 1), except for occipital area. These findings suggested 
that the cortical maturation arrest may cause FCD type Ia.
The tangential compositions of the neocortex are completed 
Table 2. The current three-tired ILAE classification system of FCD5)
FCD type I (isolated) Focal cortical dysplasia with 
abnormal radial cortical 
lamination (FCD type Ia)
Focal cortical dysplasia 
with abnormal tangential 
cortical lamination (FCD 
type Ib)
Focal cortical dysplasia with abnormal radial  and 
tangential cortical lamination (FCD type Ic)
FCD type II (isolated) Focal cortical dysplasia with dysmorphic neurons (FCD 
type IIa)
Focal cortical dysplasia with dysmorphic neurons and 
balloon cells (FCD type IIb)
FCD type III (associated with 
principal lesion)
Cortical lamination 
abnormalities in the 
temporal lobe associated 
with hippocampal sclerosis 
(FCD type IIIa)
Cortical lamination 
abnormalities adjacent to a 
glial or glioneuronal tumor 
(FCD type IIIb)
Cortical lamination 
abnormalities adjacent to 
vascular malformation (FCD 
type IIIc)
Cortical lamination 
abnormalities adjacent to 
any other lesion acquired 
during early life, e.g., 
trauma, ischemic injury, 
encephalitis (FCD type IIId)
FCD type III (NOS) : if clinically/radiologically suspected principal lesion is not available for microscopic inspection. Please note that the rare association 
between FCD type IIa and IIb with hippocampal sclerosis, tumors, or vascular malformations should not be classified as FCD type III variant. ILAE : 
international league against epilepsy, FCD : focal cortical dysplasia, NOS : not otherwise specified
Fig. 7. FCD type IIIa is a hippocampal sclerosis (ILAE type Ia) showing neuronal loss in CA4, 3, 2 and 1 (A; NeuN, ×12) with associating FCD type Ib which shows a 
breakdown of cortical tangential composition in overlying cortex (B; NeuN, ×40). FCD : focal cortical dysplasia.
A B
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after the radial migration. The tangential composition looks 
like “concentric lamella” (Fig. 1, red lines). Usually The FCD 
type Ib shows the derangements of cortical six-layers (Fig. 4).
The FCD type Ic is the combination of both variants. Even 
the neuropathologic experts doubts whether it is real entity or 
not. 
FCD type II
These are undoubtedly definite categories. Also in Palmini 
et al.’s classification11), these entities were almost the same. The 
hallmark of these FCD variants were presence of cortical dys-
lamination and dysmorphic neurons without (FCD type IIa) 
(Fig. 5) or with balloon cells (FCD type IIb) (Fig. 6)5). In the 
ILAE classification of FCD, the detailed morphological defi-
Table 3. Suggestions for an update to the ILAE classification of FCD10)
Histology Update needed Comments
FCD type I (isolated)
FCD type Ia Abnormal radial cortical lamination Yes Molecular biomarkers needed to confirm specific 
pathomechanism
FCD type Ib Abnormal tangential cortical lamination Yes Molecular biomarkers needed to confirm specific 
pathomechanism
FCD type Ic Abnormal radial and tangential cortical 
lamination
No Molecular biomarkers needed to confirm specific 
pathomechanism
FCD type II (isolated)
FCD type IIa Dysmorphic neurons Yes Introduce genetic findings of mTOR activation
FCD type IIb Dysmorphic neurons and balloon cells Yes Introduce genetic findings of mTOR activation and 
new variant at bottom‐of‐sulcus
FCD type III (associated)
FCD type IIIa Cortical lamination abnormalities in 
the temporal lobe associated with 
hippocampal sclerosis
No Molecular and clinical biomarkers needed to 
differentiate between secondary (acquired) or 
primary etiology
FCD type IIIb Cortical lamination abnormalities adjacent 
to a glial or glioneuronal tumor
No Molecular and clinical biomarkers needed to 
differentiate between secondary (acquired) or 
primary etiology
FCD type IIIc Cortical lamination abnormalities adjacent 
to vascular malformation
No Molecular and clinical biomarkers needed to 
differentiate between secondary (acquired) or 
primary etiology
FCD type IIId Cortical lamination abnormalities adjacent 
to any other lesion acquired during early 
life
Yes Molecular and clinical biomarkers needed to 
differentiate between secondary (acquired) or 
primary etiology; introduce FCD type IIId with loss 
of layer four neurons in occipital lobe
ILAE : international league against epilepsy, FCD : focal cortical dysplasia, mTOR : mammalian target of rapamycin
A B C D
Fig. 8. FCD type IIIb is combined with a low grade-epilepsy associated tumor (LEAT). Diagnosis of “the associated tumor” in this case is dysembryoplastic neuro-
epithelial tumor (DNT) (A; H-E, ×12 and B; H-E, ×200). Overlying cortex shows FCD type Ia (C; NeuN, ×40) characterized by microcolumns (D; red box; NeuN, ×200). 
FCD : focal cortical dysplasia.
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nitions of dysmorphic neurons (cell size 16–43 µm, nucleus 
diameter 15–28 µm, the characteristic Nissl substance and 
immunohistochemical stainings)5) were emphasized. More-
over, the morphological and immunohistochemical features 
of balloon cells were detailed5).
FCD type III
The FCD type III is classified into four subcategories (Table 2) 
based on histological features of principal lesion. If histologi-
cal examination is not available, it is recommended to use Not 
Otherwise Specified (NOS). The concept of FCD type III can 
be simply defined as FCD type I adjacent to another principal 
lesion. For understanding of this concept, it is better to men-
tion “Temporal lobe sclerosis”15). Thom et al.15) reported ap-
proximately 10% of HS cases showed a horizontal cortical 
dyslamination with neuronal loss in temporal neocortex. Re-
f lecting their frequent association, co-existence of HS and 
FCD type I are classified as FCD IIIa (Fig. 7), but not as con-
current type I and type III. Similarly, FCD type I associated 
with other lesions (such as tumor, vascular lesion, and etc.) 
were classified as FCD type IIIb (Fig. 8), IIIc, and IIId, respec-
tively.
It is not well known about the pathogenesis of FCD type III. 
As noted above, it is very difficult to differentiate whether the 
cortical dyslamination was primary or secondary. 
Limitations, genetic progress and prospect
In our opinion, major limitation of this system is low inter-
observer agreement, especially, occurring in the assessment of 
type I and III. In addition, the definition of mMCD was still 
not clearly established. Nowadays, a lot of research papers re-
garding genetic information in FCD are published. Detailed 
review of the updates in genetics of FCD is beyond the pur-
pose of this paper. Briefly, recent genomic data suggests that 
alteration of mammalian target of rapamycin (mTOR) path-
way and mutations of Tuberous sclerosis (TSC) gene play an 
important role in pathogenesis of FCD9,10). With the advanced 
knowledge in genetics, it is needed to update the current clas-
sification10). The concept of integrated diagnosis upon clinico-
pathological and molecular findings has been recently sug-
gested (Table 3). The authors carefully expect that the next 
classification system of FCD might be similar to the current 
World Health Organization (WHO) central nervous system 
(CNS) tumor classification.
There is no “perfect” disease classification system. Accord-
ing to technical progressions and disease paradigm changes, it 
should be updated. This virtuous cycle will be essential to 
make better disease classification. This effort will provide a 
better medical care for patient with epilepsy.
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